Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.895 +0.065 (+3.55%)
Streaming Delayed Price Updated: 3:14 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 320,173
Open 1.830
Bid (Size) 1.890 (400)
Ask (Size) 1.900 (700)
Prev. Close 1.830
Today's Range 1.800 - 1.920
52wk Range 1.150 - 2.350
Shares Outstanding 5,847,955
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment ↗
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls. 
Via Benzinga
OS Animal Health Featured in Coverage of the Disruptive Growth & Life Sciences Conference
Via Investor Brand Network

Performance

YTD
+41.4%
+41.4%
1 Month
+16.3%
+16.3%
3 Month
+8.9%
+8.9%
6 Month
+16.3%
+16.3%
1 Year
-15.4%
-15.4%

More News

Read More
News headline image
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Via Newsfile
InvestorNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push
Via Investor Brand Network
News headline image
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Via Newsfile
News headline image
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Via Newsfile
News headline image
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Third Quarter 2026 Corporate Outlook
Via Newsfile
News headline image
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
Via Newsfile
News headline image
OS Therapies Provides U.S. Regulatory Update
Via Newsfile
News headline image
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
Via Newsfile
News headline image
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
Via Newsfile
Topics Death Intellectual Property
News headline image
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
Via Newsfile
News headline image
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
Via Newsfile
News headline image
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
Via Newsfile
Topics Regulatory Compliance
News headline image
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
Via Newsfile
News headline image
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
Via Newsfile
News headline image
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
Via Newsfile
News headline image
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
From The Rosen Law Firm, P.A.
Via Business Wire

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?
Yes, OS Therapies Incorporated Common Stock is publicly traded.
What exchange does OS Therapies Incorporated Common Stock trade on?
OS Therapies Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for OS Therapies Incorporated Common Stock?
The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange
What is the current price of OS Therapies Incorporated Common Stock?
The current price of OS Therapies Incorporated Common Stock is 1.895
When was OS Therapies Incorporated Common Stock last traded?
The last trade of OS Therapies Incorporated Common Stock was at 09/09/26 03:14 PM ET
What is the market capitalization of OS Therapies Incorporated Common Stock?
The market capitalization of OS Therapies Incorporated Common Stock is 11.08M
How many shares of OS Therapies Incorporated Common Stock are outstanding?
OS Therapies Incorporated Common Stock has 11M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.